Pluri Inc. announced that its CDMO division (PluriCDMO?) has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions. PluriCDMO? will support Remedy Cell?s production team in the manufacturing of a clinical-grade Working Cell Bank (WCB) and GMP batches of Remedy Cell?s drug candidate RC-0315, derived from mesenchymal stem cells, towards the launch of their Phase Ib clinical trial for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a lethal, complex, progressive interstitial lung disorder with a median survival of 3.8 years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.78 USD | +7.53% |
|
+16.30% | +24.68% |
18/06 | Sector Update: Consumer Stocks Ease in Late Afternoon Trading | MT |
18/06 | Sector Update: Consumer | MT |
1st Jan change | Capi. | |
---|---|---|
+24.68% | 3.11Cr | |
+38.65% | 3.94TCr | |
-8.62% | 3.85TCr | |
+26.95% | 3.07TCr | |
+10.74% | 2.59TCr | |
-13.50% | 2.6TCr | |
+44.87% | 1.41TCr | |
+34.36% | 1.27TCr | |
-7.14% | 1.13TCr | |
-12.61% | 1.06TCr |
- Stock Market
- Equities
- PLUR Stock
- News Pluri Inc.
- Pluri Selected as Cdmo by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing